SR
SRBCF.US Sirona Biochem Corp
- Market cap
- USD 1.63M
- P/E
- -
- P/B
- 36.93x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Jul 2024.
Is SRBCF.US undervalued?
Graham numberThe Graham number of Sirona Biochem Corp cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Sirona Biochem Corp fundamental analysis
No fundamental analysis for Sirona Biochem Corp yet.
Sirona Biochem Corp stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Sirona Biochem Corp
Sirona Biochem Corp., a cosmetic ingredient and drug discovery company, engages in the development and sale of cosmetic and pharmaceutical active ingredients in Canada and France. The company's programs include cosmetic skin lightener and diabetes drug; and other projects comprise the development of an anti-aging/cell protection library, anti-wrinkle compound, and anti-viral program. The company was formerly known as High Rider Capital Inc. and changed its name to Sirona Bio…
Full company profileSirona Biochem Corp financial statements
2024 annualized: Fiscal year 2024 is not finished. Income statement and cash flow are annualized from 3 quarters up to Jul 31, 2024, the balance sheet is the latest quarter. Figures change when the annual report is published.
Sirona Biochem Corp annual financial statements (CAD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 208K | 8.00K | 361K | 5.47K | 1.28M | 136K | 106K | 268K | 672K | 34.8K | 20.2K |
| Gross Profit | 151K | -205K | 310K | 5.47K | 1.28M | 136K | 51.6K | 199K | 622K | -28.8K | 13.8K |
| Operating Income | -3.48M | -3.50M | -2.93M | -2.49M | -912K | -4.44M | -4.04M | -2.35M | -3.57M | -2.41M | -2.33M |
| EBITDA | -3.46M | -3.40M | -2.79M | -2.30M | -912K | -4.44M | -4.12M | -2.30M | -3.52M | -2.33M | -2.31M |
| Net Income | -3.53M | -3.55M | -2.97M | -4.46M | -1.27M | -4.55M | -4.13M | -2.31M | -3.56M | -2.54M | -2.71M |
| EPS | -0.03 | -0.03 | -0.02 | -0.03 | -0.01 | -0.02 | -0.02 | -0.01 | -0.01 | -0.01 | -0.01 |
| Balance Sheet | |||||||||||
| Total Assets | 3.43M | 4.75M | 3.13M | 1.25M | 771K | 4.26M | 2.14M | 1.29M | 1.29M | 1.03M | 809K |
| Total Liabilities | 1.64M | 2.40M | 1.56M | 3.29M | 3.03M | 2.07M | 2.09M | 1.38M | 1.08M | 3.54M | 4.27M |
| Shareholders' Equity | 1.79M | 2.35M | 1.56M | -2.04M | -2.26M | 2.19M | 47.4K | -97.0K | 215K | -2.51M | -3.46M |
| Cash & Short-term Investments | 613K | 1.54M | 613K | 273K | 339K | 3.73M | 1.54M | 778K | 422K | 572K | 33.6K |
| Total Debt | 674K | 1.40M | 969K | 2.69M | 2.51M | 1.55M | 1.24M | 851K | 470K | 2.18M | 3.32M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -1.86M | -2.58M | -2.10M | -2.50M | -654K | -3.56M | -2.11M | -2.16M | -2.18M | -1.76M | -2.38M |
| Capital Expenditure | 235K | 327K | 136K | 176K | 47.0K | 47.0K | 47.0K | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -2.09M | -2.91M | -2.24M | -2.67M | -654K | -3.56M | -2.16M | -2.16M | -2.18M | -1.76M | -2.38M |
| Ratios | |||||||||||
| ROE | -196.9% | -151.0% | -190.3% | - | - | -207.8% | -8,721.9% | - | -1,658.5% | - | - |
| ROA | -102.9% | -74.7% | -95.2% | -356.5% | -165.2% | -106.9% | -193.4% | -179.1% | -275.6% | -246.4% | -335.3% |
| Net Profit Margin | -1,697.2% | -44,354.5% | -825.2% | -81,572.7% | -99.6% | -3,351.6% | -3,910.4% | -860.5% | -529.5% | -7,312.4% | -13,399.9% |
| Debt to Equity | 0.38x | 0.59x | 0.62x | - | - | 0.71x | 26.20x | - | 2.19x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Sirona Biochem Corp dividends
Sirona Biochem Corp has not paid dividends in the last 9 fiscal years.
Who owns Sirona Biochem Corp
- Insiders 4.19%
- Institutions 0.00%
- Public & others 95.81%
- Shares outstanding 259M
- Free float 248M
Sirona Biochem Corp company profile
- Company name
- Sirona Biochem Corp
- Ticker
- SRBCF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- October
- Address
- 595 Burrard Street, Vancouver, BC, Canada, V7X 1L4
- Phone
- 604 641 4466
- Website
- sironabiochem.com
About Sirona Biochem Corp
Sirona Biochem Corp., a cosmetic ingredient and drug discovery company, engages in the development and sale of cosmetic and pharmaceutical active ingredients in Canada and France. The company's programs include cosmetic skin lightener and diabetes drug; and other projects comprise the development of an anti-aging/cell protection library, anti-wrinkle compound, and anti-viral program. The company was formerly known as High Rider Capital Inc. and changed its name to Sirona Biochem Corp. in May 2009. Sirona Biochem Corp. was incorporated in 2006 and is headquartered in Vancouver, Canada.
Sirona Biochem Corp management
3- Dr. Howard J. Verrico M.D., Ph.D.Founder, Chairman of the Board, CEO & Secretary · born 1961
- Mr. Christopher D. Hopton C.G.A., CPACFO & Director · born 1966
- Dr. Géraldine Deliencourt-Godefroy Ph.D.Chief Scientific Officer & Director